Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.

ABSTRACT:

Objective

To investigate the safety and efficacy of rituximab in multiple sclerosis (MS).

Methods

In this retrospective uncontrolled observational multicenter study, off-label rituximab-treated patients with MS were identified through the Swedish MS register. Outcome data were collected from the MS register and medical charts. Adverse events (AEs) grades 2-5 according to the Common Terminology Criteria for Adverse Events were recorded.

Results

A total of 822 rituximab-treated patients with MS were identified: 557 relapsing-remitting MS (RRMS), 198 secondary progressive MS (SPMS), and 67 primary progressive MS (PPMS). At baseline, 26.2% had contrast-enhancing lesions (CELs). Patients were treated with 500 or 1,000 mg rituximab IV every 6-12 months, during a mean 21.8 (

SUBMITTER: Salzer J 

PROVIDER: S-EPMC5109942 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature